Listar por autor "Sánchez-Muñoz, Alfonso"
Mostrando ítems 1-20 de 27
-
A Carboxylesterase 2 Gene Polymorphism as Predictor of Capecitabine on Response and Time to Progression
Ribelles, Nuria; López-Siles, J; Sánchez-Muñoz, Alfonso
; Sánchez, E; González, E; Sánchez, MJ; Carabantes, F; Sánchez- Rovira, P; Márquez, A; Dueñas, R; Sevilla, I; Alba-Conejo, Emilio[et al.] (Bentham Science Publishers Ltd, 2008)
Capecitabine is a drug that requires the consecutive action of three enzymes: carboxylesterase 2 (CES 2), cytidine deaminase (CDD), and thymidine phosphorylase (TP) for transformation into 5-fluorouracil (5FU). The ... -
A microRNA signature associated with early recurrence in breast cancer.
Pérez-Rivas, Luis G.; Jerez-Aragonés, José Manuel; Carmona, Rosario; De Luque, Vanessa; Vicioso-Recio, Luis Prudencio; Claros-Díaz, Manuel Gonzalo; Viguera-Mínguez, Enrique; Pajares, Bella; Sánchez-Muñoz, Alfonso; Ribelles, Nuria; Alba-Conejo, Emilio; Lozano-Castro, José[et al.] (PLOS, 2014-03-14)
Recurrent breast cancer occurring after the initial treatment is associated with poor outcome. A bimodal relapse pattern after surgery for primary tumor has been described with peaks of early and late recurrence occurring ... -
A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study
Alba-Conejo, Emilio; Chacón, J. L.; Lluc, A.; Antón, A.; Estévez, L.; Cirauqui, B.; Carrasco, E.; Calvo, L.; Seguí, M.A.; Ribelles, Nuria; Álvarez, R.; Sánchez-Muñoz, Alfonso; Sánchez, R.; Lopez Garcia-Asenjo, J.A.; Rodriguez-Martin, C.; Escudero, M.J.; Albanell, J.[et al.] (Springer, 2012-10)
Abstract Chemotherapy remains as the only systemic treatment option available for basal-like breast cancer (BC) patients. Preclinical models and several phase II studies suggested that platinum salts are active drugs in ... -
Assessment of Procalcitonin as a Diagnostic and Prognostic Marker in Patients with Solid Tumors and Febrile Neutropenia
Jimeno, Antonio; García-Velasco, Adelaida; del Val, Olga; González-Billalabeitia, Enrique; Hernando, Susana; Hernández, Rosario; Sánchez-Muñoz, Alfonso; López-Martın, Ana; Durán, Ignacio; Robles, Luis; Corté-Funes, Hernán; Paz-Ares, Luis[et al.] (Wiley InterScience, 2004-03)
Cancer patients with fever and neutropenia currently are assessed on clinical grounds only. The current study prospectively evaluated the efficacy of baseline procalcitonin (PCT) in the detection of bacteremia and in the ... -
Association of Circular RNA and Long Non-Coding RNA Dysregulation with the Clinical Response to Immune Checkpoint Blockade in Cutaneous Metastatic Melanoma.
Oliver, Javier; Onieva Zafra, Juan Luis; Garrido-Barros, María; Berciano-Guerrero, Miguel Ángel; Sánchez-Muñoz, Alfonso; Lozano, María José; Farngren, Angela; Álvarez-Pérez, Martina; Martínez-Gálvez, Beatriz; Pérez-Ruiz, Elisabeth; Alba-Conejo, Emilio; Cobo Dols, Manuel Ángel; Rueda-Domínguez, Antonio; Barragán, Isabel[et al.] (MDPI, 2022)
Cutaneous melanoma (CM) is the most lethal form of skin cancer if it becomes metastatic, where treatment options and survival chances decrease dramatically. Immunotherapy treatments based on the immunologic checkpoint ... -
Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer
Sánchez-Muñoz, Alfonso; Mendiola, César; Pérez-Ruiz, Elisabeth; Rodríguez-Sánchez, César A.; Jurado, José Miguel; Alonso-Carrión, Lorenzo Javier; Ghanem, Ismael; Velasco, Guillermo de; Quero-Blanco, Cristina; Alba-Conejo, Emilio[et al.] (KARGER, 2010-11)
Aim: To retrospectively assess the efficacy and safety of bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Patients and Methods: Patients with recurrent ... -
Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications.
Godoy-Ortiz, Ana; Sánchez-Muñoz, Alfonso; Chica Parrado, María del Rosario; Álvarez-Pérez, Martína; Ribelles, Nuria; Rueda-Domínguez, Antonio; Alba-Conejo, Emilio[et al.] (Frontiers Media, 2019)
The main obstacle for designing effective treatment approaches in breast cancer is the extensive and the characteristic heterogeneity of this tumor. The vast majority of critical genomic changes occurs during breast cancer ... -
Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data.
Díaz-Redondo, Tamara; Lavado Valenzuela, Rocío; Jiménez-Rodríguez, Begoña; Pascual, Tomás; Gálvez, Fernando; Falcón, Alejandro; Álamo, María del Carmen; Morales-Estévez, Cristina; Amerigo, Marta; Pascual, Javier; Sánchez-Muñoz, Alfonso; González-Guerrero, Macarena; Vicioso-Recio, Luis Prudencio; Laborda-Illanes, Aurora; Ortega-Jiménez, María Victoria; Pérez-Villa, Lidia; Fernández-Martínez, Aranzazu; Chic, Nuria; Jerez-Aragonés, José Manuel; Álvarez-Pérez, Martína; Prat, Aleix; Ribelles, Nuria; Alba-Conejo, Emilio[et al.] (Frontiers Media, 2019)
Double blockade with pertuzumab and trastuzumab combined with chemotherapy is the standard neoadjuvant treatment for HER2-positive early breast cancer. Data derived from clinical trials indicates that the response rates ... -
Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study.
Pivot, X.; Verma, S.; Fallowfield, L.; Müller, M.; Lichinitser, M.; Jenkins, V.; Sánchez-Muñoz, Alfonso; Machackova, Z.; Osborne, S.; Gligorov, J.[et al.] (Elsevier, 2017-09-28)
Aim: To assess efficacy (event-free survival, EFS) and safety in patients followed up for 3 years in the PrefHer study (NCT01401166). Patients and methods: Post surgery and post chemotherapy in the (neo)adjuvant setting, ... -
High IGKC-Expressing Intratumoral Plasma Cells Predict Response to Immune Checkpoint Blockade.
Onieva Zafra, Juan Luis; Xiao, Qingyang; Berciano-Guerrero, Miguel Ángel; Laborda-Illanes, Aurora; de Andrea, Carlos; Chaves, Patricia; Piñeiro Pereda, María del Pilar; Garrido-Aranda, Alicia; Gallego-Domínguez, Elena María; Sojo, Belén; Gálvez Carvajal, Laura; Chica Parrado, María del Rosario; Prieto Cuadra, Juan Daniel; Pérez-Ruiz, Elisabeth; Farngren, Angela; Lozano, María José; Álvarez-Pérez, Martína; Jiménez, Pedro; Sánchez-Muñoz, Alfonso; Oliver, Javier; Cobo Dols, Manuel Ángel; Alba-Conejo, Emilio; Barragán, Isabel[et al.] (MDPI, 2022)
Resistance to Immune Checkpoint Blockade (ICB) constitutes the current limiting factor for the optimal implementation of this novel therapy, which otherwise demonstrates durable responses with acceptable toxicity scores. ... -
Identificación de una firma de expresión génica mediante el sistema de análisis nCounter como marcador pronóstico de recaída en pacientes con tumores de células germinales no seminoma estadio I
(UMA Editorial, 2020-09-16)INTRODUCCIÓN Actualmente para el 15-20% de los pacientes con tumores de células germinales (TCG) mestastásicos las opciones curativas son limitadas, estando en investigación la respuesta a terapias diana. La infiltración ... -
Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer.
Sánchez-Muñoz, Alfonso; Gallego-Domínguez, Elena María; De Luque, Vanessa; Pérez-Rivas, Luis G.; Vicioso-Recio, Luis Prudencio; Ribelles, Nuria; Lozano-Castro, José; Alba-Conejo, Emilio[et al.] (Springer Nature, 2010-04-13)
Background: Mutational analysis of the KRAS gene has recently been established as a complementary in vitro diagnostic tool for the identification of patients with colorectal cancer who will not benefit from anti-epidermal ... -
Machine learning and natural language processing (NLP) approach to predict early progression to first-line treatment in real-world hormone receptor-positive (HRþ)/HER2-negative advanced breast cancer patients.
Ribelles, Nuria; Jerez-Aragonés, José Manuel; Rodríguez-Brazzarola, Pablo; Jiménez-Rodríguez, Begoña; Díaz-Redondo, Tamara; Mesa, Héctor; Márquez, Antonia; Sánchez-Muñoz, Alfonso; Pajares, Bella; Carabantes, Francisco; Bermejo-Pérez, María José; Villar, Ester; Domínguez-Recio, María Emilia; Saez-Lara, Enrique; Gálvez Carvajal, Laura; Godoy-Ortiz, Ana; Franco, Leónardo; Ruiz-Medina, Sofía; López, Irene; Alba-Conejo, Emilio[et al.] (Elsevier, 2021)
Background: CDK4/6 inhibitors plus endocrine therapies are the current standard of care in the first-line treatment of HRþ/HER2-negative metastatic breast cancer, but there are no well-established clinical or molecular ... -
Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes
Sánchez-Muñoz, Alfonso; Vicioso-Recio, Luis Prudencio; Santonja, Angela; Alvaréz, Martina; Plata-Fernández, Yéssica; Miramón, José; Zarcos, Irene; Ramírez-Tortosa, César; Montes-Torres, Julio; Jerez-Aragonés, José Manuel; De Luque, Vanessa; Llácer, Casilda; Fernández-De Sousa, C.E.; Pérez-Villa, Lidia; Alba-Conejo, Emilio[et al.] (Elsevier, 2018-02)
Male breast cancer is a rare disease that is still poorly understood. It is mainly classified by immunohistochemistry as a luminal disease. In this study, we assess for the first time the correlation between molecular ... -
Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes.
Sánchez-Muñoz, Alfonso; Vicioso-Recio, Luis Prudencio; Santonja, Ángela; Álvarez-Pérez, Martína; Plata-Fernández, Yéssica; Miramón, José; Zarcos, Irene; Ramírez-Tortosa, C.L.; Montes-Torres, Julio; Jérez, J.M.; De Luque, Vanessa; Llácer, Casilda; Fernández-De Sousa, C.E.; Pérez-Villa, Lidia; Alba-Conejo, Emilio[et al.] (Elsevier, 2017-09-22)
Male breast cancer is a rare disease that is still poorly understood. It is mainly classified by immunohistochemistry as a luminal disease. In this study, we assess for the first time the correlation between molecular ... -
Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index.
Ribelles, Nuria; Jerez-Aragonés, José Manuel; Pajares, Bella; Vicioso-Recio, Luis Prudencio; Jiménez-Rodríguez, Begoña; De Luque, Vanessa; Franco, Leónardo; Gallego-Domínguez, Elena María; Márquez, Antonia; Álvarez, Martina; Sánchez-Muñoz, Alfonso; Pérez-Rivas, Luis G.; Alba-Conejo, Emilio; Ribelles, Nuria[et al.] (BMC, 2013-10-22)
Recurrence risk in breast cancer varies throughout the follow-up time. We examined if these changes are related to the level of expression of the proliferation pathway and intrinsic subtypes. Results: Luminal A displayed ... -
Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG)
Aparicio, Jorge; Maroto, Pablo; García del Muro, Xavier; Sánchez-Muñoz, Alfonso; Guma, Josep; Margelí, Mireia; Sáenz, Alberto; Sagastibelza, Naiara; Castellano, Daniel; Arranz-Arija, José Ángel; Hervás, David; Bastús, Romá; Fernández-Aramburo, Antonio; Sastre, Javier; Terrasa, Josefa; Lopez-Brea, Marta; Dorca, Joan; Almenar, Daniel; Carles, J.; Hernández, Álvaro; Germá-Lluch, José Ramón[et al.] (Elsevier, 2014-09-10)
Background: We aimed to analyze prognostic factors for relapse in stage I seminoma managed by either active surveillance or adjuvant chemotherapy, and to describe the long-term patterns of recurrence in both groups. Patients ... -
Prognostic Significance of Venous Thromboembolic Events in Disseminated Germ Cell Cancer Patients.
González-Billalabeitia, Enrique; Castellano, Daniel; Sobrevilla, Nora; Guma, Josep; Hervás, David; Luengo, María I.; Aparicio, Jorge; Sánchez-Muñoz, Alfonso; Mellado, Begoña; Sáenz, Alberto; Valverde, Claudia; Fernández, Antonio; Margelí, Mireia; Durán, Ignacio; Fernández, Sara; Sastre, Javier; Ros, Silverio; Maroto, Pablo; Manneh, Ray; Cerezuela, Pablo; Carmona-Bayonas, Alberto; Ayala de la Peña, Francisco; Aguilar, José Luis; Rivera, Samuel; García del Muro, Xavier; Germá-Lluch, José Ramón[et al.] (Oxford Academic, 2017-01-26)
Background: Disseminated germ cell cancers are at high risk of developing thromboembolic complications. We evaluated the prognostic value of venous thromboembolic events (VTE) in disseminated germ cell cancer. Results: ... -
Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER1) node-negative breast cancer
Albanell, J.; González, A.; Ruiz-Borrego, M; Alba-Conejo, Emilio; García-Saenz, J.A.; Corominas, J. M.; Burgues, O.; Furio, V.; Rojo, A.; Palacios, J.; Bermejo, B.; Martínez-García, M.; Limón, L.M.; Sánchez-Muñoz, Alfonso; Martín, M.; Tusquets, I.; Rojo, R.; Colomer, R.; Faull, F.; Lluch, A.[et al.] (Elsevier, 2012-03)
This study examined the impact of the Recurrence Score (RS) in Spanish breast cancer patients and explored the associations between clinicopathological markers and likelihood of change in treatment recommendations. Patients ... -
Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER).
Albanell, J.; Martínez-García, M.; Ramos-Boyero, Manuel; O'Connor, Miriam; De-la-Cruz-Merino, Luis; Santaballa-Bertrán, Ana; Martínez-Jáñez, Noelia; Moreno-Antón, Fernando; Fernández, Isaura; Alarcón, Jesús Damián; Virizuela-Echaburu, Javier Antonio; De-la-Haba-Rodríguez, Juan Rafael; Sánchez- Rovira, P; González-Cortijo, Lucía; Margelí, Mireia; Sánchez-Muñoz, Alfonso; Antón, A.; Casas, María Isabel; Bezares, Susana; Rojo, Federico[et al.] (Elsevier, 2022)
Background: The potential benefit of adding palbociclib to fulvestrant as first-line treatment in hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative endocrine-sensitive advanced breast ...